Frederico M. Asch, MD presented analysis from his late breaking clinical trial, COAPT. The echocardiography characteristics of the COAPT population, strengthens the need to identify a consistent baseline for enrolling patients in an effort to replicate similar results when used in clinical practice. “…clearly the fact that the results were so different, the outcomes were so different, makes it extremely important that we understand who exactly was enrolled in COAPT,” Asch said. Learn more.
Washington, D.C., (December 4, 2018) —MedStar Heart in partnership with CardioCell has been approved to conduct an investigational new drug clinical trial, called STEMVAD at MedStar Heart & Vascular Institute. The goal of this study is to determine whether stem cell therapy improves myocardial function in patients with severe heart failure. “Innovative therapies to improve heart function and outcomes of patients with advanced heart failure are sorely needed,” said Selma Mohammed, MD, PhD. Read more.
- COVID-19: Results from the MedStar Health CDC Community Research Partnership (CRP) Study of COVID-19
MedStar Health has been conducting a large scale, multi-site Centers for Disease Control and Prevent...
- COVID-19: MedStar Health Receives FDA Clearance to Trial an Oral Immunomodulatory Drug for COVID-19
Over the past year, our research team Dr. Thomas Fishbein, Dr. Khalid Khan and Dr. Alexander Kroemer...
- COVID-19: MedStar Health Investigators Evaluate Substance Use Trends during the COVID-19 Pandemic
Collaborative research from MedStar Health Research Institute, MedStar Washington Hospital Center, G...
The researchers from MedStar Heart & Vascular Institute, led by Ron Waksman, MD, found, in their first-of-its-kind trial, that transcatheter aortic valve replacement in patients with low surgical risk showed no deaths or disabling strokes within 30 days of undergoing the procedure. This is a “strong signal” that it is safe for these patients as an alternative to the current standard of care. Read more.